Laddar...
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
BACKGROUND: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre-existing cardiovascular disease. These attribute...
Sparad:
| I publikationen: | Mol Metab |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Elsevier
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085566/ https://ncbi.nlm.nih.gov/pubmed/32987188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101090 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|